Axsome Therapeutics, Inc. (AXSM)

Axsome Therapeutics is a biopharmaceutical company focused on developing and delivering medicines for central nervous system (CNS) conditions. It identifies gaps in care and develops differentiated products with novel mechanisms of action. Its stated aim is to become a fully integrated company that develops and commercializes therapies for CNS disorders. It uses proprietary medicinal chemistry and formulation technologies, including chiral chemistry, metabolic inhibition as a drug delivery method, the MoSEIC (Molecular Solubility Enhanced Inclusion Complex) technology to increase solubility and speed absorption, and proprietary chemical synthesis and analysis.

The company has three commercial products for major depressive disorder (MDD) and for excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea, plus a recently approved migraine product. Auvelity (dextromethorphan-bupropion, also called AXS-05) is an oral treatment for MDD in adults, FDA-approved in August 2022 and launched in the U.S. in October 2022. Sunosi (solriamfetol) treats EDS in patients with narcolepsy or obstructive sleep apnea. Axsome acquired the U.S. rights from Jazz Pharmaceuticals in May 2022 and the ex-U.S. rights, excluding certain Asian markets, in November 2022. SK Biopharmaceuticals, the originator, retains rights in 12 Asian markets. In February 2023, Axsome licensed Sunosi marketing rights in Europe and certain Middle East and North Africa countries to Pharmanovia. Symbravo (meloxicam-rizatriptan, AXS-07) uses MoSEIC technology and was FDA-approved in January 2025 for the acute treatment of migraine with or without aura in adults. The development pipeline includes AXS-05 for Alzheimer's disease agitation (FDA Breakthrough Therapy designation, with a completed Phase 3 program) and for smoking cessation (a positive Phase 2 trial with Duke University). It also includes AXS-12 (reboxetine) for narcolepsy, with FDA Orphan Drug Designation and positive Phase 2 and Phase 3 trials, and AXS-14 (esreboxetine) for fibromyalgia, based on data in-licensed from Pfizer. Solriamfetol is in four Phase 3 trials for ADHD, MDD, binge eating disorder, and shift work disorder.

The company targets CNS indications with high unmet medical need, noting that its approved products and candidates address conditions affecting over 150 million people in the United States. Examples include Alzheimer's disease, which affects about 7 million people in the U.S., with about 70% of patients experiencing agitation. Axsome plans to commercialize in the U.S. through its own focused sales and marketing organization and to selectively partner commercial rights outside the U.S.

Its strategy includes using well-characterized molecules and, where possible, the FDA's 505(b)(2) regulatory pathway to reduce clinical and regulatory risk and development costs. Its products and candidates are protected by patents, trade secrets, and know-how, with patents for AXS-05 extending to 2043, AXS-12 to 2039, Symbravo to 2040, and Sunosi to 2042. Patent litigation settlements with Unichem (Sunosi) and Teva (Auvelity) allow generic entry no earlier than June 2042 and September 2038, respectively, in most cases. The text does not describe manufacturing, suppliers, or headquarters.